PL444560A1 - Application of the IMA biomarker - Google Patents

Application of the IMA biomarker

Info

Publication number
PL444560A1
PL444560A1 PL444560A PL44456023A PL444560A1 PL 444560 A1 PL444560 A1 PL 444560A1 PL 444560 A PL444560 A PL 444560A PL 44456023 A PL44456023 A PL 44456023A PL 444560 A1 PL444560 A1 PL 444560A1
Authority
PL
Poland
Prior art keywords
ima
biomarker
application
saliva
ischemia
Prior art date
Application number
PL444560A
Other languages
Polish (pl)
Inventor
Mateusz MACIEJCZYK
Julita Szulimowska
Anna ZALEWSKA
Katarzyna Taranta-Janusz
Małgorzata Żendzian-Piotrowska
Original Assignee
Uniwersytet Medyczny W Białymstoku
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniwersytet Medyczny W Białymstoku filed Critical Uniwersytet Medyczny W Białymstoku
Priority to PL444560A priority Critical patent/PL444560A1/en
Publication of PL444560A1 publication Critical patent/PL444560A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Zgłoszenie wynalazku dotyczy zastosowania stężenia albuminy modyfikowanej niedokrwieniem (IMA) w ślinie jako biomarkera do oceny in vitro chorób nerek, zwłaszcza w populacji pediatrycznej.The invention relates to the use of ischemia-modified albumin (IMA) concentration in saliva as a biomarker for in vitro assessment of kidney diseases, especially in the pediatric population.

PL444560A 2023-04-25 2023-04-25 Application of the IMA biomarker PL444560A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL444560A PL444560A1 (en) 2023-04-25 2023-04-25 Application of the IMA biomarker

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL444560A PL444560A1 (en) 2023-04-25 2023-04-25 Application of the IMA biomarker

Publications (1)

Publication Number Publication Date
PL444560A1 true PL444560A1 (en) 2024-10-28

Family

ID=93289675

Family Applications (1)

Application Number Title Priority Date Filing Date
PL444560A PL444560A1 (en) 2023-04-25 2023-04-25 Application of the IMA biomarker

Country Status (1)

Country Link
PL (1) PL444560A1 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012012469A2 (en) * 2010-07-19 2012-01-26 Otago Innovation Limited Signal biomarkers

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012012469A2 (en) * 2010-07-19 2012-01-26 Otago Innovation Limited Signal biomarkers

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
OZKURT, S. ET AL.: "Saudi J Kidney Dis Transpl 2021; 32(4):1006-1012", "ASSESSMENT OF ISCHEMIA MODIFIED ALBUMIN AS A MARKER OF OXIDATIVE STRESS IN CHRONIC KIDNEY DISEASE" *
UZUN, M. ET AL.: "Journal of the American Society of Nephrology, Abstract Supplement, November 2015, vol. 26, abstrakt SA-PO202 str. 671A", "USEFULNESS OF SERUM ISCHEMIA-MODIFIED ALBUMIN LEVELS TO PREDICT DIALYSIS REQIREMENT IN PATIENTS WITH ACUTE RENAL INJURY" *

Similar Documents

Publication Publication Date Title
CY1126062T1 (en) STABLE PHARMACEUTICAL FORM OF ANTI-IFNAR1
CY1121672T1 (en) ANTIBODIES THAT BIND IL-17A AND IL-17F
EA201991701A1 (en) COMPOSITION BASED ON MONOCLONAL ANTIBODY TO RSV
CO2020009402A2 (en) Fc il-22 fusion proteins and methods of use
MX2021011715A (en) ANTIBODIES AGAINST AMYLOID-? WITH PYROGLUTAMATE AND USES OF THESE FIELD OF THE INVENTION.
CY1111714T1 (en) Binding Protein Growth Factor (HGF) Binding Proteins.
ATE475672T1 (en) ANTI-IL-23 ANTIBODIES
SA523451800B1 (en) Anti-sirp-alpha antibodies
EA201892202A1 (en) METHODS OF TREATMENT OF CHOLESTATIC DISEASES
CL2011000010A1 (en) Monoclonal anti-beta-amyloid peptide antibody; polynucleotide that encodes it; hybridoma; Method of production; composition comprising it; use to treat diseases related to amyloid proteins; method of diagnosing them; and kit that includes it.
CY1116377T1 (en) Suspensions of Human Tyrosine Protein Phosphate and Methods of Use
ATE534667T1 (en) ANTI-ABETA ANTIBODIES
NO20083697L (en) Methods for using antibodies against human IL-22
EA200801427A1 (en) ANTIBODY MOLECULES WITH SPECIFIC ACTIVITY WITH RESPECT TO HUMAN INTERLEUKIN-6 (IL-6)
NO20073175L (en) Antigenic epitopes of interleukin-21, related antibodies and their use in the medical field
MX2020007628A (en) Compositions and methods of use.
JOP20220204B1 (en) human CD19 antibodies
MX2022000654A (en) FLUORESCENT SYSTEMS FOR BIOLOGICAL IMAGES AND THEIR USES.
PL444560A1 (en) Application of the IMA biomarker
CO2022019225A2 (en) Anti-hbv antibodies and methods of use
MX2024006208A (en) ANTI-TREM2 ANTIBODY AND ITS USES.
WO2022031920A3 (en) End stage renal disease biomarker panel
JOP20240233A1 (en) Mutant CD24 proteins and their uses in cancer prevention and treatment
ATE503476T1 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES CAUSED BY INFECTION WITH YERSINIA SPP
EA202192418A1 (en) METHODS OF TREATMENT OF AL-AMYLOIDOSIS